目的：利用美国癌症基因组图谱（TCGA）及基因型-组织表达（GTEx）等数据库研究卵巢癌中转导素β1X连锁受体蛋白1（TBL1XR1）的基因拷贝数扩增情况，探讨TBL1XR1参与卵巢癌发生发展的可能机制。方法：从TCGA、GTEx等数据库收集卵巢癌数据及患者的临床资料，研究TBL1XR1的基因拷贝数扩增情况与卵巢癌患者的临床病理特征的关系，分析TBL1XR1的基因拷贝数扩增情况与TBL1XR1 mRNA及蛋白表达水平的相关性；研究TBL1XR1基因在肿瘤组织和正常样本中表达的差异及其与临床分期的关系；研究TBL1XR1基因拷贝数扩增及表达与卵巢癌患者预后的相关性。结果：28.7%的卵巢癌样本的TBL1XR1基因拷贝数发生扩增。样本的TBL1XR1基因拷贝数扩增与其mRNA表达[r=0.584（Pearson法），r=0.590（Spearman法）]及蛋白表达[r=0.629（Pearson法），r=0.599（Spearman法）]均呈正相关（P<0.01）。TBL1XR1基因在卵巢癌组织中表达显著高于正常组织（P<0.01）。不同临床分期的卵巢癌TBL1XR1基因表达差异有统计学意义（F=5.51，P=0.004），进一步两两比较发现，卵巢癌Ⅱ期与Ⅲ期的表达差异有统计学意义，其他临床分期之间差异均无统计学意义。不同TBL1XR1基因拷贝数扩增水平的卵巢癌患者总生存率（OS）、无病生存率（DFS）差异有统计学意义（P=0.015 0、P=0.041 2）。卵巢癌TBL1XR1基因高表达的患者与低表达患者相比，OS和DFS显著缩短（P=0.002，P=0.024）。结论：TBL1XR1基因拷贝数扩增是卵巢癌预后较差的因素之一，可作为判断预后的标记物。

[1] CORNELISON R,LLANEZA D C,LANDEN C N.Emerging therapeutics to overcome chemoresistance in epithelial ovarian cancer:a mini-review[J].Int J Mol Sci,2017,18(10):2171.
[2] XU M,GUO J C,ZHANG J,et al.Protein-coding genes,long non-coding RNAs combined with microRNAs as a novel clinical multi-dimension transcriptome signature to predict prognosis in ovarian cancer[J].Oncotarget,2017,8(42):72847-72859.
[3] LIU F,GAO H,ZHAO Y,et al.Transducin (beta)-like 1 X-linked receptor 1 correlates with clinical prognosis and clinicopathological characteristics in human solid carcinomas[J].Oncotarget,2017,8(37):61626-61636.
[4] ZHOU Q,WANG X,YU Z,et al.Transducin (beta)-like 1 X-linked receptor 1 promotes gastric cancer progression via the ERK1/2 pathway[J].Oncogene,2017,36(13):1873-1886.
[5] LIU F,HE Y,CAO Q,et al.TBL1XR1 is highly expressed in gastric cancer and predicts poor prognosis[J].Dis Markers,2016,2016:2436518.
[6] DANIELS G,ZHANG X,ZHONG X,et al.Cytoplasmic,full length and novel cleaved variant,TBLR1 reduces apoptosis in prostate cancer under androgen deprivation[J].Oncotarget,2016,7(26):39556-39571.
[7] SIEGEL R,MA J,ZOU Z,et al.Cancer statistics,2014[J].CA Cancer J Clin,2014,64(1):9-29.
[8] ZHANG X,DORMADY S P,BASCH R S.Identification of four human cDNAs that are differentially expressed by early hematopoietic progenitors[J].Exp Hematol,2000,28(11):1286-1296.
[9] ZHANG X M,CHANG Q,ZENG L,et al.TBLR1 regulates the expression of nuclear hormone receptor co-repressors[J].BMC Cell Biol,2006,7:31.
[10] WU X,ZHAN Y,LI X,et al.Nuclear TBLR1 as an ER corepressor promotes cell proliferation,migration and invasion in breast and ovarian cancer[J].Am J Cancer Res,2016,6(10):2351-2360.
[11] PARK S Y,NA Y,LEE M H,et al.SUMOylation of TBL1 and TBLR1 promotes androgen-independent prostate cancer cell growth[J].Oncotarget,2016,7(27):41110-41122.
[12] LI J Y,DANIELS G,WANG J,et al.TBL1XR1 in physiological and pathological states[J].Am J Clin Exp Urol,2015,3(1):13-23.
[13] LIU Y,SUN W,ZHANG K,et al.Identification of genes differentially expressed in human primary lung squamous cell carcinoma[J].Lung Cancer,2007,56(3):307-317.